Trial Profile
A Phase III, Multicenter, Randomized, Double-Blind Trial to Assess the Safety and Efficacy of Two Parallel Dose Groups of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients With Gaucher Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Taliglucerase alfa (Primary)
- Indications Gaucher's disease
- Focus Therapeutic Use
- Sponsors Protalix Biotherapeutics
- 20 Jun 2014 New trial record